Plain-English translation of NCT05518578 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Epilepsy research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it's safe and can be tolerated by people with treatment-resistant epilepsy — a type of seizure disorder that hasn't improved with other medications. The study will involve about 60 adults and will last about 21 weeks of active treatment, with an optional extension period afterward. Researchers want to understand how well this medication works and what side effects people might experience.
Many people with epilepsy continue to have seizures even after trying multiple medications. This trial exists to find new treatment options for these patients and to understand whether this medication could help reduce seizures while being safe to use.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll start with an 8-week screening period where doctors confirm your diagnosis and establish a baseline. Then you'll enter a 9-week titration period where you'll gradually start taking the medication (starting at a low dose and increasing it), followed by a 12-week maintenance period where you take a stable dose. Throughout this 21-week treatment period, you'll visit the clinic regularly, keep a seizure diary, and report any side effects. After completing the main study, you'll have the option to continue in an extended phase for up to 52 additional weeks.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States
Australia